Drug intelligence / Profile preview

Chinese Academy of Medical Sciences & Peking Union Medical College FOXM1 compound S2

Development stage: Unknown
Lead developer: Chinese Academy of Medical Sciences Peking Union Medical College

Overview

Chinese Academy of Medical Sciences & Peking Union Medical College FOXM1 compound S2: sourced facts only. name: "Compound S2 showed a stronger affinity for FOXM1 and improved its activity with a broad-spectrum anticancer effect." [PMID:36334454]; target: "Compound S2 showed a stronger affinity for FOXM1 and improved its activity with a broad-spectrum anticancer effect." [PMID:36334454]; developer: "Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China." [PMID:36334454]

Targets

FOXM1 (Forkhead box protein M1)

Beyond the preview

Go deeper on Chinese Academy of Medical Sciences & Peking Union Medical College FOXM1 compound S2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chinese Academy of Medical Sciences & Peking Union Medical College FOXM1 compound S2.